Loading…
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2M | $-178M | $-162M | $-129M | -32.9% | -67.3% | - |
| 2024 | $6M | $-101M | $-85M | $-78M | -24.1% | 120.6% | - |
| 2023 | $3M | $-48M | $-44M | $-37M | -25.8% | -56.0% | - |
| 2022 | $6M | $-30M | $-28M | $-29M | -38.7% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 6.42 | 2.83 | 6.24 | 2.04 |
| Operating Expense | 36.12 | 51 | 108.10 | 179.97 |
| Operating Income | -29.70 | -48.17 | -101.86 | -177.93 |
| EBITDA | -29.56 | -47.82 | -101.45 | -177.50 |
| EBIT | -29.70 | -48.17 | -101.86 | -177.93 |
| Pretax Income | -28.48 | -43.55 | -84.97 | -162.34 |
| Net Income | -28.48 | -43.55 | -84.97 | -162.34 |
| Net Income Common Stockholders | -28.48 | -43.55 | -84.97 | -162.34 |
| Total Expenses | 36.12 | 51 | 108.10 | 179.97 |
| Interest Income | 1.15 | 4.76 | 17.36 | 16.12 |
| Research And Development | 29.38 | 32.84 | 83.11 | 145.64 |
| Selling General And Administration | 6.74 | 18.16 | 24.99 | 34.33 |
| Normalized EBITDA | -29.69 | -47.73 | -101.54 | -177.96 |
| Normalized Income | -28.61 | -43.47 | -85.05 | -162.79 |
| Basic EPS | -1.92 | -8.45 | -2.55 | 0 |
| Diluted EPS | -1.92 | -8.45 | -2.55 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0.14 | -0.09 | 0.08 | 0.45 |
| Total Unusual Items Excluding Goodwill | 0.14 | -0.09 | 0.08 | 0.45 |
| Net Income From Continuing Operation Net Minority Interest | -28.48 | -43.55 | -84.97 | -162.34 |
| Reconciled Depreciation | 0.15 | 0.35 | 0.41 | 0.43 |
| Net Interest Income | 1.15 | 4.76 | 17.36 | 16.12 |
| Net Income From Continuing And Discontinued Operation | -28.48 | -43.55 | -84.97 | -162.34 |
| Total Operating Income As Reported | -29.70 | -48.17 | -101.86 | -177.93 |
| Diluted Average Shares | 14.82 | 5.15 | 33.31 | 0 |
| Basic Average Shares | 14.82 | 5.15 | 33.31 | 0 |
| Diluted NI Availto Com Stockholders | -28.48 | -43.55 | -84.97 | -162.34 |
| Net Income Including Noncontrolling Interests | -28.48 | -43.55 | -84.97 | -162.34 |
| Net Income Continuous Operations | -28.48 | -43.55 | -84.97 | -162.34 |
| Other Income Expense | 0.08 | -0.14 | -0.47 | -0.52 |
| Other Non Operating Income Expenses | -0.05 | -0.06 | -0.55 | -0.97 |
| Gain On Sale Of Security | 0.14 | -0.09 | 0.08 | 0.45 |
| Net Non Operating Interest Income Expense | 1.15 | 4.76 | 17.36 | 16.12 |
| Interest Income Non Operating | 1.15 | 4.76 | 17.36 | 16.12 |
| General And Administrative Expense | 6.74 | 18.16 | 24.99 | 34.33 |
| Other Gand A | 6.74 | 18.16 | 24.99 | 34.33 |
| Operating Revenue | 6.42 | 2.83 | 6.24 | 2.04 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Dianthus Therapeutics, Inc.this co. | DNTH | $4.5B | - | 7.31 | -32.9% | -18.62 |
| Lantheus Holdings, Inc. | LNTH | $5.3B | 23.80 | 4.81 | 21.4% | 14.41 |
| PACS Group, Inc. | PACS | $5.2B | 27.38 | 5.53 | 20.1% | 23.70 |
| CRISPR Therapeutics AG | CRSP | $4.9B | - | 2.53 | -30.3% | -5.64 |
| Amicus Therapeutics, Inc. | FOLD | $4.5B |
| - |
| 16.43 |
| -9.9% |
| 112.00 |
| Alignment Healthcare, Inc. | ALHC | $4.5B | - | 24.74 | -0.4% | 90.31 |
| Option Care Health, Inc. | OPCH | $4.2B | 21.16 | 3.18 | 15.7% | 12.82 |
| Crinetics Pharmaceuticals, Inc. | CRNX | $4.0B | - | 3.70 | -46.9% | -5.94 |
| iRhythm Holdings, Inc. | IRTC | $4.0B | - | 25.53 | -29.2% | -132.48 |
| Peer Median | - | 23.80 | 5.17 | -5.1% | 13.61 | |